YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells

被引:1
|
作者
Nakajima, Maako [1 ]
Tanaka, Kentaro [1 ]
Yoneshima, Yasuto [1 ]
Yamashita, Sho [1 ]
Shibahara, Daisuke [1 ]
Iwama, Eiji [1 ]
Okamoto, Isamu [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, 3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan
基金
日本学术振兴会;
关键词
Yes-associated protein (YAP); Epidermal growth factor (EGF); Epidermal growth factor receptor (EGFR); Non-small cell lung cancer; Apoptosis; Hippo pathway; GROWTH-FACTOR RECEPTOR; HIPPO PATHWAY; MECHANISMS; MUTATIONS;
D O I
10.1016/j.bbrc.2023.09.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mechanisms underlying the growth and survival of non-small cell lung cancer (NSCLC) cells positive for activating mutations of the epidermal growth factor receptor gene (EGFR) have remained unclear. We here examined the functional relation between such mutant forms of EGFR and Yes-associated protein (YAP), a transcriptional coactivator of the Hippo signaling pathway that regulates cell proliferation and survival. Under the condition of serum deprivation, epidermal growth factor (EGF) induced activation of YAP in NSCLC cell lines positive for mutated EGFR but not in those wild type (WT) for EGFR. Similar EGF-induced activation of YAP was apparent in A549 lung cancer cells forcibly expressing mutant EGFR but not in those overexpressing the WT receptor. Furthermore, EGF induced apoptotic cell death in serum-deprived A549 cells overexpressing the WT form of EGFR but not in those expressing mutant EGFR, and knockdown of YAP rendered the latter cells sensitive to this effect of EGF. Our results thus suggest that activation of YAP mediates resistance of EGFR-mutated NSCLC cells to EGF-induced apoptosis and thereby contributes specifically to the survival of such cells.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 50 条
  • [31] Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
    Inoue, Akira
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2020, 96 (07): : 266 - 272
  • [32] Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
    Zhao, Q.
    Deng, L.
    Zhang, Y.
    Zhou, X.
    Li, Y.
    Yu, M.
    Zhou, L.
    Zou, B.
    Liu, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Lara-Mejia, Luis
    Sanchez-Reyes, Roberto
    Aviles-Salas, Alejandro
    Arrieta-Rodriguez, Oscar
    ONCOLOGY-NEW YORK, 2020, 34 (01): : 21 - 27
  • [34] Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
    Zeng, Beilei
    Gan, Kelun
    Yu, Yuanhang
    Hu, Jianping
    Deng, Qiao
    Yin, Chong
    Gao, Xi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms
    Proto, Claudia
    Lo Russo, Giuseppe
    Corrao, Giulia
    Ganzinelli, Monica
    Facchinetti, Francesco
    Minari, Roberta
    Tiseo, Marcello
    Garassino, Marina Chiara
    TUMORI JOURNAL, 2017, 103 (04): : 325 - 337
  • [36] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
    Bertoli, Elisa
    De Carlo, Elisa
    Del Conte, Alessandro
    Stanzione, Brigida
    Revelant, Alberto
    Fassetta, Kelly
    Spina, Michele
    Bearz, Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [37] Identification of Immune Checkpoint Inhibitor Therapeutic Resistance Factors in EGFR-mutated Non-Small Cell Lung Cancer
    Nakajima, Wataru
    Ishino, Kousuke
    Miyazaki, Kai
    Ohashi, Ryuji
    Yamamoto, Hayashi
    CANCER SCIENCE, 2024, 115 : 682 - 682
  • [38] Targeting FGFR to overcome EMT-related resistance in EGFR-mutated non-small cell lung cancer
    Raoof, Sana
    Ruddy, David
    Timonia, Daria
    Damon, Leah
    Engelman, Jeff
    Hata, Aaron
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [39] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [40] Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
    Koulouris, Andreas
    Tsagkaris, Christos
    Corriero, Anna Chiara
    Metro, Giulio
    Mountzios, Giannis
    CANCERS, 2022, 14 (14)